Ocrevus is now FDA approved to treat relapsing-remitting multiple sclerosis in children aged 10 years and older weighing at least 25kg.

The US FDA has approved ocrelizumab (Ocrevus, Genentech) intravenous infusion for children aged 10 years and older with relapsing-remitting multiple sclerosis (RRMS) who weigh at least 55 lbs (25 kg), ...

Eating greater amounts of ultra-processed foods is significantly associated with a higher likelihood MS in childhood or ...

AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in ...

Rakan fought his cancer, a rare form of pediatric kidney cancer known as diffused anaplastic Wilms’s tumor, with a ferocity ...

MS is three times more common in females than in males. Females are more likely to have relapsing forms of MS, with an earlier onset than men. Menstrual changes and more intense fatigue and pain are ...

Prognostic communication in pediatric oncology can be fraught with conflicting preferences.“In the same room, one parent may ...

Broward Children's Center (BCC) – a nonprofit organization dedicated to serving infants, children and young adults who are ...

A new Canada-U.S. study has found that higher consumption of ultra-processed foods is strongly associated with an increased likelihood of developing pediatric-onset multiple sclerosis (POMS). Each 10% ...

The FDA has approved IV ocrelizumab for treatment of relapsing-remitting MS in children and adolescents aged 10 years and ...

VCU pediatric hospital taps first COO, Katie Golob, to oversee Children's Hospital of Richmond's operations and growth initiatives.

Children were more likely to undergo an evaluation if they had public insurance, had a higher BMI, had English as a primary ...